Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.

Suzuki K, Terui Y, Yokoyama M, Ueda K, Nishimura N, Mishima Y, Sakajiri S, Tsuyama N, Takeuchi K, Hatake K.

Leuk Lymphoma. 2013 Nov;54(11):2412-7. doi: 10.3109/10428194.2013.779690.

PMID:
23488601
2.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

3.

Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.

Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.

Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x. Epub 2011 Jul 26.

PMID:
21575062
4.

The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.

Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, Lee SW, Huh J, Suh C.

Ann Hematol. 2012 Nov;91(11):1731-9. doi: 10.1007/s00277-012-1512-4. Epub 2012 Jul 3.

PMID:
22752193
5.

Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.

Nakamura N, Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Sawada M, Yamada T, Seishima M, Takami T, Moriwaki H.

Eur J Haematol. 2013 Oct;91(4):322-31. doi: 10.1111/ejh.12139. Epub 2013 Jul 7.

PMID:
23672298
6.

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.

J Clin Oncol. 2012 Oct 1;30(28):3460-7. Epub 2012 Jun 4.

PMID:
22665537
7.

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E; MabThera International Trial (MInT) Group.

Lancet Oncol. 2008 May;9(5):435-44. doi: 10.1016/S1470-2045(08)70078-0. Epub 2008 Apr 8.

PMID:
18400558
8.

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.

Tai WM, Quah D, Yap SP, Tan SH, Tang T, Tay KW, Koo YX, Tao M, Quek R, Lim ST.

Leuk Lymphoma. 2011 Apr;52(4):604-12. doi: 10.3109/10428194.2010.550073. Epub 2011 Jan 24.

PMID:
21261504
9.

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.

Mato A, Feldman T, Zielonka T, Singavi A, Gadaletta G, Waksmundzki K, Bhattacharyya P, Chow KF, Yang X, Panush D, Agress H, Rosario M, Howlett C, Pecora A, Goy A.

Leuk Lymphoma. 2013 Dec;54(12):2606-12. doi: 10.3109/10428194.2013.783909. Epub 2013 May 15.

PMID:
23488604
10.

A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.

Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M.

Anticancer Res. 2014 May;34(5):2559-64.

PMID:
24778077
11.

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.

Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M.

Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28.

PMID:
22712840
12.

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.

Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.

Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.

PMID:
25521006
13.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
14.
15.

Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.

J Clin Oncol. 2011 Apr 10;29(11):1452-7. doi: 10.1200/JCO.2010.33.3419. Epub 2011 Mar 7.

PMID:
21383296
16.
17.

A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.

Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S, Tenant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K.

Leuk Lymphoma. 2013 Sep;54(9):1921-7. doi: 10.3109/10428194.2012.754024. Epub 2013 Jan 4.

PMID:
23206228
18.

Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.

Hong J, Park S, Park J, Kim HS, Kim KH, Ahn JY, Rim MY, Jung M, Sym SJ, Cho EK, Shin DB, Lee JH.

Leuk Lymphoma. 2011 Oct;52(10):1904-12. doi: 10.3109/10428194.2011.588761. Epub 2011 Jun 30.

PMID:
21718130
19.

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.

Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.

Leuk Lymphoma. 2012 Sep;53(9):1757-63. doi: 10.3109/10428194.2012.670231. Epub 2012 Apr 19.

PMID:
22372848
20.

Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.

Aoki K, Takahashi T, Tabata S, Kurata M, Matsushita A, Nagai K, Ishikawa T.

Leuk Lymphoma. 2013 Nov;54(11):2441-7. doi: 10.3109/10428194.2013.780654. Epub 2013 Apr 17.

PMID:
23452117

Supplemental Content

Support Center